GDC-0575 freebase

• CAT Number: I027991
• CAS Number: 1196541-47-5
• Molecular Formula: C16H20BrN5O
• Molecular Weight: 378.27
• Purity: 98%
• Synonyms: GDC-0575; GDC 0575; GDC0575; ARRY-575; ARRY-575; ARRY575; RG7741; RG-7741; RG 7741; AK 687476; AK-687476; AK687476; GDC-0575 HCl; GDC-0575 hydrochloride
• Target: Checkpoint Kinase (Chk)
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Store at -20°C
• IUPAC Name: N-[4-[(3R)-3-aminopiperidin-1-yl]-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl]cyclopropanecarboxamide
• InChI: InChI=1S/C16H20BrN5O/c17-11-6-19-15-13(14(11)22-5-1-2-10(18)8-22)12(7-20-15)21-16(23)9-3-4-9/h6-7,9-10H,1-5,8,18H2,(H,19,20)(H,21,23)/t10-/m1/s1
• InChIKey: BAZRWWGASYWYGB-SNVBAGLBSA-N
• SMILES: C1C[C@H](CN(C1)C2=C3C(=CNC3=NC=C2Br)NC(=O)C4CC4)N

GDC-0575 freebase（Cat No.:I027991）is a highly selective inhibitor of checkpoint kinase 1 (CHK1), a key regulator of the DNA damage response and cell cycle progression. By inhibiting CHK1, GDC-0575 enhances the effects of DNA-damaging agents, leading to increased DNA damage and apoptosis, particularly in cancer cells with defective DNA repair mechanisms. It is being investigated for use in combination with chemotherapies and radiation therapy to potentiate antitumor activity. GDC-0575 shows promise in treating various cancers, especially those relying on CHK1 for survival in response to genotoxic stress.

Reference

1: Grellety T, Callens C, Richard E, Briaux A, Vélasco V, Pulido M, Gonçalvès A, Gestraud P, MacGrogan G, Bonnefoi H, Cardinaud B. Enhancing abiraterone acetate efficacy in androgen receptor-positive triple negative breast cancer: Chk1 as a potential target. Clin Cancer Res. 2018 Oct 23. pii: clincanres.1469.2018. doi: 10.1158/1078-0432.CCR-18-1469. [Epub ahead of print] PubMed PMID: 30352905.
2: Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. Ann Oncol. 2018 Feb 23. doi: 10.1093/annonc/mdy076. [Epub ahead of print] PubMed PMID: 29788155.
3: Oo ZY, Stevenson AJ, Proctor M, Daignault SM, Walpole S, Lanagan C, Chen J, Škalamera D, Spoerri L, Ainger SA, Sturm RA, Haass NK, Gabrielli B. Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo. Clin Cancer Res. 2018 Jun 15;24(12):2901-2912. doi: 10.1158/1078-0432.CCR-17-2701. Epub 2018 Mar 13. PubMed PMID: 29535131.
4: Laroche-Clary A, Lucchesi C, Rey C, Verbeke S, Bourdon A, Chaire V, Algéo MP, Cousin S, Toulmonde M, Vélasco V, Shutzman J, Savina A, Le Loarer F, Italiano A. CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Ann Oncol. 2018 Apr 1;29(4):1023-1029. doi: 10.1093/annonc/mdy039. PubMed PMID: 29409053.
5: Di Tullio A, Rouault-Pierre K, Abarrategi A, Mian S, Grey W, Gribben J, Stewart A, Blackwood E, Bonnet D. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun. 2017 Nov 22;8(1):1679. doi: 10.1038/s41467-017-01834-4. PubMed PMID: 29162833; PubMed Central PMCID: PMC5698422.